BRPI0315959B8 - composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto - Google Patents
composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do compostoInfo
- Publication number
- BRPI0315959B8 BRPI0315959B8 BRPI0315959A BR0315959A BRPI0315959B8 BR PI0315959 B8 BRPI0315959 B8 BR PI0315959B8 BR PI0315959 A BRPI0315959 A BR PI0315959A BR 0315959 A BR0315959 A BR 0315959A BR PI0315959 B8 BRPI0315959 B8 BR PI0315959B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- overweight
- treatment
- pharmaceutical composition
- mortality associated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 238000000034 method Methods 0.000 title 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto". a presente invenção refere-se a novos compostos de narilasulfonila-3- indolo substituído, seus derivados, seus análogos, suas formas tautoméricas, seus estereoisômeros, suas formas geométricas, seus n-óxidos, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceuticamente aceitáveis e às composições farmaceuticamente aceitáveis contendo os mesmos. a presente invenção refere-se particularmente aos novos n-arilasulfonila-3-indolos substituídos tendo a fórmula (i) , seus derivados, seus análogos, suas formas tautoméricas, seus estereoisômeros, suas formas geométricas, seus óxidos de n, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceuticamente aceitáveis e às composições farmaceuticamente aceitáveis contendo os mesmos. a presente invenção também refere-se ao processo para a preparação dos compostos da fórmula (i), as composições farmacêuticas que contém tais compostos e ao uso de tais compostos e composições na medicina. esta invenção também está relacionada aos intermediários inovadores envolvidos nos mesmos e ao processo para a sua preparação.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN884MA2002 | 2002-11-28 | ||
IN884/MAS/2002 | 2002-11-28 | ||
PCT/IN2003/000209 WO2004048330A1 (en) | 2002-11-28 | 2003-06-05 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
Publications (4)
Publication Number | Publication Date |
---|---|
BR0315959A BR0315959A (pt) | 2005-09-13 |
BRPI0315959B1 BRPI0315959B1 (pt) | 2017-12-19 |
BRPI0315959B8 true BRPI0315959B8 (pt) | 2018-01-16 |
BRPI0315959C1 BRPI0315959C1 (pt) | 2021-05-25 |
Family
ID=40184827
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0315959A BRPI0315959C1 (pt) | 2002-11-28 | 2003-06-05 | composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto |
BRPI0318799A BRPI0318799B8 (pt) | 2002-11-28 | 2003-06-05 | processo para a preparação de um composto |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0318799A BRPI0318799B8 (pt) | 2002-11-28 | 2003-06-05 | processo para a preparação de um composto |
Country Status (22)
Country | Link |
---|---|
US (1) | US7875605B2 (pt) |
EP (1) | EP1581492B1 (pt) |
JP (1) | JP4559230B2 (pt) |
KR (1) | KR100818508B1 (pt) |
CN (2) | CN1720225B (pt) |
AT (1) | ATE401307T1 (pt) |
AU (1) | AU2003237599B2 (pt) |
BR (2) | BRPI0315959C1 (pt) |
CA (1) | CA2509982C (pt) |
CY (1) | CY1108786T1 (pt) |
DE (1) | DE60322266D1 (pt) |
DK (1) | DK1581492T3 (pt) |
EA (1) | EA011320B1 (pt) |
ES (1) | ES2310243T3 (pt) |
HK (2) | HK1133002A1 (pt) |
MX (1) | MXPA05005701A (pt) |
NO (2) | NO330341B1 (pt) |
NZ (2) | NZ540840A (pt) |
PT (1) | PT1581492E (pt) |
SI (1) | SI1581492T1 (pt) |
WO (1) | WO2004048330A1 (pt) |
ZA (1) | ZA200504043B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068220A1 (en) * | 2002-02-12 | 2003-08-21 | Akzo Nobel N.V. | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders |
WO2005005439A1 (en) * | 2003-07-09 | 2005-01-20 | Suven Life Sciences Limited | Benzothiazino indoles |
CA2552106C (en) | 2004-01-02 | 2011-10-11 | Suven Life Sciences Limited | Novel indeno[2,1a]indenes and isoindol[2,1-a]indoles |
WO2007014851A2 (en) | 2005-07-29 | 2007-02-08 | F. Hoffmann-La Roche Ag | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
JP5091138B2 (ja) | 2005-08-12 | 2012-12-05 | スヴェン・ライフ・サイエンシズ・リミテッド | 機能性5−ht6リガンドとしてのアミノアリールスルホンアミド誘導体 |
WO2007020653A1 (en) * | 2005-08-12 | 2007-02-22 | Suven Life Sciences Limited | Thioether derivatives as functional 5-ht6 ligands |
KR101250820B1 (ko) | 2005-08-16 | 2013-04-04 | 수벤 라이프 사이언시스 리미티드 | 개선된 로사르탄 제조 방법 |
BRPI0718736A2 (pt) * | 2007-01-08 | 2014-03-25 | Suven Life Sciences Ltd | " compostos inovadores de 4- (heterociclila) alquila -n- (arilasulfonila) indolo e seu uso como ligantes de 5ht6" |
DK2114878T3 (da) | 2007-01-08 | 2011-03-14 | Suven Life Sciences Ltd | 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander |
SI2155674T1 (sl) | 2007-05-03 | 2011-10-28 | Suven Life Sciences Ltd | Aminoalkoksi aril sulfonamid spojine in njih uporaba kot 5-ht6 ligandi |
WO2008144263A1 (en) * | 2007-05-18 | 2008-11-27 | The Ohio State University Research Foundation | Potent indole-3-carbinol-derived antitumor agents |
CA2703157C (en) | 2007-10-26 | 2013-02-05 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
EA019496B1 (ru) | 2008-09-17 | 2014-04-30 | Сувен Лайф Сайенсиз Лимитед | Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht |
WO2011019738A1 (en) * | 2009-08-10 | 2011-02-17 | Galenea Corporation | Compounds and methods of use thereof |
US8153680B2 (en) | 2009-08-25 | 2012-04-10 | The Ohio State University Research Foundation | Alkyl indole-3-carbinol-derived antitumor agents |
CN102869647B (zh) | 2010-01-05 | 2015-06-24 | 苏文生命科学有限公司 | 作为5-ht6受体配体的砜化合物 |
CN102093149A (zh) * | 2010-12-08 | 2011-06-15 | 天津理工大学 | 一种促进氰基快速水解制备羧酸类化合物的方法 |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
KR101534136B1 (ko) * | 2013-06-11 | 2015-07-07 | 이화여자대학교 산학협력단 | 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
EA028038B1 (ru) | 2013-12-02 | 2017-09-29 | Сувен Лайф Сайенсиз Лимитед | Способ для промышленного производства 1-[(2-бромфенил)сульфонил]-5-метокси-3-[(4-метил-1-пиперазинил)метил]-1h-индол димезилат моногидрата |
JP6454346B2 (ja) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族複素環式化合物及び医薬におけるその応用 |
CN105541693B (zh) | 2014-07-08 | 2018-10-16 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
PL3180001T3 (pl) | 2014-08-16 | 2019-07-31 | Suven Life Sciences Limited | Aktywny metabolit monohydrat dimesylanu 1-[(2-bromofenylo)sulfonylo]-5-metoksy-3-[(4-metylo-1-piperazynylo)metylo]-1h-indolu oraz sól dihydrat dimesylanu aktywnego metabolitu |
JP6629464B2 (ja) * | 2016-05-18 | 2020-01-15 | スヴェン・ライフ・サイエンシズ・リミテッド | 純粋な5−ht6受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びnmda受容体アンタゴニストの3種類の組合せ |
JP6606298B2 (ja) * | 2016-05-18 | 2019-11-13 | スヴェン・ライフ・サイエンシズ・リミテッド | 純粋な5−ht6受容体アンタゴニストのnmda受容体アンタゴニストとの組合せ |
PT3484467T (pt) * | 2016-05-18 | 2020-06-16 | Suven Life Sciences Ltd | Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase |
WO2018065869A1 (en) * | 2016-10-03 | 2018-04-12 | Suven Life Sciences Limited | Pharmaceutical compositions of 5-ht6 antagonist |
CN107174586B (zh) * | 2017-02-21 | 2020-08-11 | 中国科学院昆明植物研究所 | 以芦竹碱衍生物为活性成分的药物组合物及其应用 |
SG11201913104QA (en) * | 2017-07-03 | 2020-01-30 | Suven Life Sciences Ltd | New uses of a pure 5-ht 6 receptor antagonist |
WO2021111330A1 (en) | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
JP2023510082A (ja) | 2019-12-02 | 2023-03-13 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者における行動・心理症状を治療するための方法 |
CN111233737B (zh) * | 2020-03-16 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
CN111362858B (zh) * | 2020-03-16 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
KR102347372B1 (ko) | 2020-12-14 | 2022-01-07 | (주)케이메디켐 | 신규한 인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
CN115504925B (zh) * | 2021-06-22 | 2024-03-12 | 广东药科大学 | 一类ppar激动剂、其制备方法及其作为药物的用途 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1305458A (pt) * | 1969-02-26 | 1973-01-31 | ||
ZA795239B (en) | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
ZA815541B (en) | 1980-08-12 | 1983-03-30 | Glaxo Group Ltd | Heterocyclic compounds |
GB8600397D0 (en) | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
GB8719167D0 (en) | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
GB8724912D0 (en) | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
GB8819024D0 (en) | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
JPH04208263A (ja) * | 1990-01-02 | 1992-07-29 | Fujisawa Pharmaceut Co Ltd | インドール誘導体およびそれらの製造法 |
IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
CA2042295A1 (fr) | 1990-05-15 | 1991-11-16 | Jacques Chauveau | Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant |
HU219974B (hu) | 1990-06-07 | 2001-10-28 | Astrazeneca Ab, | Heterociklusos csoporttal helyettesített indolszármazék, előállítása és a vegyületet hatóanyagként tartalmazó gyógyszerkészítmények |
SK278998B6 (sk) | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
TW263508B (pt) | 1991-02-12 | 1995-11-21 | Pfizer | |
GB9113802D0 (en) | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
JP3223193B2 (ja) * | 1991-08-09 | 2001-10-29 | 株式会社日清製粉グループ本社 | インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質 |
GB9210400D0 (en) | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
KR940007001A (ko) | 1992-09-16 | 1994-04-26 | 최승주 | 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제 |
EP0773942A1 (en) | 1994-07-26 | 1997-05-21 | Pfizer Inc. | 4-indole derivatives as serotonin agonists and antagonists |
CA2370147C (en) * | 1999-04-21 | 2009-07-28 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-ht6 affinity |
JP2000344744A (ja) * | 1999-06-04 | 2000-12-12 | Ss Pharmaceut Co Ltd | アセトフェノン誘導体およびその製法 |
PE20020276A1 (es) * | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
CN1317276C (zh) * | 2000-09-29 | 2007-05-23 | 中国科学院上海药物研究所 | 一类吲哚基哌啶类化合物及其制备方法和用途 |
MXPA03003397A (es) * | 2000-10-20 | 2004-06-30 | Biovitrum Ab | N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia. |
AU2002220715A1 (en) * | 2000-11-24 | 2002-06-03 | Smithkline Beecham Plc | Indolsulfonyl compounds useful in the treatment of cns disorders |
EP1351688A4 (en) | 2000-12-11 | 2006-01-04 | Smithkline Beecham Corp | UROTENSIN-II RECEPTOR ANTAGONISTS |
CN1492863A (zh) * | 2000-12-22 | 2004-04-28 | 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物 | |
JP2004524295A (ja) * | 2001-01-26 | 2004-08-12 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ii受容体アンタゴニスト |
WO2003068220A1 (en) * | 2002-02-12 | 2003-08-21 | Akzo Nobel N.V. | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders |
-
2003
- 2003-06-05 US US10/536,618 patent/US7875605B2/en active Active
- 2003-06-05 CN CN038254883A patent/CN1720225B/zh not_active Expired - Lifetime
- 2003-06-05 WO PCT/IN2003/000209 patent/WO2004048330A1/en active IP Right Grant
- 2003-06-05 CN CN200910134498XA patent/CN101544592B/zh not_active Expired - Lifetime
- 2003-06-05 NZ NZ540840A patent/NZ540840A/en not_active IP Right Cessation
- 2003-06-05 SI SI200331342T patent/SI1581492T1/sl unknown
- 2003-06-05 EP EP03735970A patent/EP1581492B1/en not_active Expired - Lifetime
- 2003-06-05 JP JP2004554900A patent/JP4559230B2/ja not_active Expired - Lifetime
- 2003-06-05 NZ NZ572186A patent/NZ572186A/en not_active IP Right Cessation
- 2003-06-05 DE DE60322266T patent/DE60322266D1/de not_active Expired - Lifetime
- 2003-06-05 AU AU2003237599A patent/AU2003237599B2/en not_active Expired
- 2003-06-05 AT AT03735970T patent/ATE401307T1/de active
- 2003-06-05 CA CA2509982A patent/CA2509982C/en not_active Expired - Lifetime
- 2003-06-05 ES ES03735970T patent/ES2310243T3/es not_active Expired - Lifetime
- 2003-06-05 MX MXPA05005701A patent/MXPA05005701A/es active IP Right Grant
- 2003-06-05 BR BRPI0315959A patent/BRPI0315959C1/pt not_active IP Right Cessation
- 2003-06-05 KR KR1020057009512A patent/KR100818508B1/ko active IP Right Grant
- 2003-06-05 DK DK03735970T patent/DK1581492T3/da active
- 2003-06-05 EA EA200500881A patent/EA011320B1/ru unknown
- 2003-06-05 BR BRPI0318799A patent/BRPI0318799B8/pt active IP Right Grant
- 2003-06-05 PT PT03735970T patent/PT1581492E/pt unknown
-
2005
- 2005-05-19 ZA ZA200504043A patent/ZA200504043B/en unknown
- 2005-06-08 NO NO20052737A patent/NO330341B1/no not_active IP Right Cessation
-
2006
- 2006-03-10 HK HK09111134.5A patent/HK1133002A1/xx not_active IP Right Cessation
- 2006-03-10 HK HK06103107.8A patent/HK1083217A1/xx not_active IP Right Cessation
-
2008
- 2008-09-17 CY CY20081100999T patent/CY1108786T1/el unknown
- 2008-12-05 NO NO20085054A patent/NO335015B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0315959B8 (pt) | composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto | |
CY1111876T1 (el) | Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη | |
EA200600925A1 (ru) | Производные триазола в качестве антагонистов вазопрессина | |
BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
CY1114417T1 (el) | Ετεροκυκλικες ενωσεις, δραστικες ως αναστολεις των βητα-λακταμασων | |
BR0317435A (pt) | Derivados de pirimidina para o tratamento do crescimento celular anormal | |
BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacêutico | |
ATE324371T1 (de) | N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten | |
EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
AR053301A1 (es) | Derivados de pirazina y su uso farmaceutico | |
MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
BR0311541A (pt) | indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas | |
BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
BR0010139A (pt) | Heterociclos bicìclicos substituìdos, processo para seu preparo e seu uso como agentes anti-obesidade e hipocolesterolêmico | |
BR0316895A (pt) | Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto | |
BR0312175A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso | |
BR0312176A (pt) | Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario | |
NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler | |
BR0306861A (pt) | Combinações que compreendem epotilonas e antimetabólitos | |
AR040690A1 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar o prevenir la insuficiencia cardiaca | |
AR027644A1 (es) | Compuestos de piridacinil fenil hidrazona, composicion farmaceutica que lo comprende y metodo para el tratamiento de una falla del corazon congestiva quelo emplea | |
BR0312174A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediário e processo para a preparação de um novo intermediário | |
UY26568A1 (es) | Nuevos derivados de amidas heterocíclicas | |
UY26328A1 (es) | Derivados de amino-triazolopiridina | |
NO20025031D0 (no) | Benzoksazin- og benzotiazinderivater og anvendelsen derav i medikamenter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2777 DE 26/03/2024 POR TER SIDO INDEVIDA. |